Oncology Corporate Profile
GlycoMimetics is a clinical stage biotechnology company focused on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in which carbohydrate biology (glycobiology) plays a key role. Glycomimetics are molecules that mimic the structure of carbohydrates involved in important biological processes. Using its expertise in carbohydrate chemistry and knowledge of carbohydrate biology, GlycoMimetics is developing a pipeline of glycomimetic drug candidates that inhibit disease-related functions of carbohydrates, such as the roles they play in inflammation, cancer and infection.
|Brand / Product||Class||Area of Study||Phase||Partnership|
|GMI-1271||E-selectin antagonist||Acute Myelogenous Leukemia (AML)||II||GlycoMimetics|
|GMI-1271||E-selectin antagonist||Multiple Myeloma||I||GlycoMimetics|
|GMI-1359||CXCR4 antagonist||Various cancer types||I||GlycoMimetics|
View additional information on product candidates here »